A detailed history of Centiva Capital, LP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 26,473 shares of PCRX stock, worth $515,429. This represents 0.01% of its overall portfolio holdings.

Number of Shares
26,473
Holding current value
$515,429
% of portfolio
0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $28.46 $309,734 - $753,421
26,473 New
26,473 $398,000
Q4 2022

Feb 14, 2023

BUY
$38.19 - $57.45 $248,693 - $374,114
6,512 New
6,512 $251,000
Q4 2021

Feb 14, 2022

SELL
$47.97 - $62.21 $357,904 - $464,148
-7,461 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$54.64 - $61.3 $407,669 - $457,359
7,461 New
7,461 $417,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Centiva Capital, LP Portfolio

Follow Centiva Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Centiva Capital, LP with notifications on news.